400-998-5282
专注多肽 服务科研
400-998-5282
专注多肽 服务科研
是CTL RP1识别的HLA-B7分子在细胞表面天然呈现的表位。
编号：184699
CAS号：2022956-41-6
单字母：H2N-TPNQRQNVC-OH
The nonapeptide TPNQRQNVC peptide is the naturally presented epitope at the cell surface by HLA-B7 molecules recognized by CTL RP1
Peptide H-TPNQRQNVC-OH is a Research Peptide with significant interest within the field academic and medical research. Recent citations using H-TPNQRQNVC-OH include the following: Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1-reactive cytotoxic T cells WJ Norde, IM Overes, F Maas, H Fredrix - Blood, The Journal , 2009 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/113/10/2312/24355 4 PD WJ Norde, F Maas, W Hobo, A Korman - strategies after stem cell , 2013 - Citeseerhttps://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=84902d132325b987f60cba6224467a548cad0913#page=45 PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation WJ Norde, F Maas, W Hobo, A Korman, M Quigley - Cancer research, 2011 - AACRhttps://aacrjournals.org/cancerres/article-abstract/71/15/5111/568065 7 Improving dendritic cell vaccine immunogenicity by silencing PD W Hobo, TI Novobrantseva, H Fredrix - strategies after stem , 2013 - repository.ubn.ru.nlhttps://repository.ubn.ru.nl/bitstream/handle/2066/106929/106929.pdf#page=83 Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation W Hobo, TI Novobrantseva, H Fredrix, J Wong - Cancer Immunology , 2013 - Springerhttps://link.springer.com/article/10.1007/s00262-012-1334-1 siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells W Hobo, F Maas, N Adisty, T de Witte - Blood, The Journal , 2010 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/116/22/4501/107827 6 siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8 W Hobo, F Maas, N Adisty, T de Witte - strategies after stem , 2013 - repository.ubn.ru.nlhttps://repository.ubn.ru.nl/bitstream/handle/2066/106929/106929.pdf?sequence=1#page=70 The Aryl Hydrocarbon Receptor Antagonist StemRegenin 1 Promotes Human Plasmacytoid and Myeloid Dendritic Cell Development from CD34+ Hematopoietic S Thordardottir, BN Hangalapura, T Hutten - Stem cells and , 2014 - liebertpub.comhttps://www.liebertpub.com/doi/abs/10.1089/scd.2013.0521 StemRegenin S Thordardottir, BN Hangalapura, T Hutten, M Cossu - smadpathway.comhttps://smadpathway.com/stemregenin-1/ Clinically applicable CD34+-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses J van Eck van der Sluijs, D van Ens - Cancer Immunology , 2021 - Springerhttps://link.springer.com/article/10.1007/s00262-021-02899-3 Aberrant expression of the hematopoietic-restricted minor histocompatibility antigen LRH-1 on solid tumors results in efficient cytotoxic T cell-mediated lysis IM Overes, T Henriaca«tte Levenga, JCM Vos - Cancer immunology , 2009 - Springerhttps://link.springer.com/article/10.1007/s00262-008-0569-3 Efficient activation of LRH-1-specific CD8+ T-cell responses from transplanted leukemia patients by stimulation with P2X5 mRNA-electroporated dendritic cells IM Overes, H Fredrix, MGD Kester - Journal of , 2009 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2009/07000/A_Novel_Flow_Cytometric_Assay_for_Evaluating.1.aspx PD-L1 siRNA-mediated silencing in acute myeloid leukemia enhances anti-leukemic T cell reactivity CM Mousset, D van Ens , TJA Hutten - Improvement of T cell , 2019 - core.ac.ukhttps://core.ac.uk/download/pdf/231968075.pdf#page=130 Minor histocompatibility antigen-specific T cells C Summers, VS Sheth, M Bleakley - Frontiers in Pediatrics, 2020 - frontiersin.orghttps://www.frontiersin.org/articles/10.3389/fped.2020.00284/full A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia B de Rijke, A van Horssen-Zoetbrood - The Journal of , 2005 - Am Soc Clin Investighttps://www.jci.org/articles/view/24832
| DOI | 名称 | |
|---|---|---|
| 10.1172/JCI24832 | A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia | 下载 |
| 10.1038/icb.2010.124 | Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia | 下载 |
多肽H2N-Thr-Pro-Asn-Gln-Arg-Gln-Asn-Val-Cys-COOH的合成步骤：
1、合成CTC树脂：称取1.26g CTC Resin（如初始取代度约为0.63mmol/g）和0.95mmol Fmoc-Cys(Trt)-OH于反应器中，加入适量DCM溶解氨基酸（需要注意，此时CTC树脂体积会增大好几倍，避免DCM溶液过少），再加入2.38mmol DIPEA（Mw：129.1,d：0.740g/ml），反应2-3小时后，可不抽滤溶液，直接加入1ml的HPLC级甲醇，封端半小时。依次用DMF洗涤2次，甲醇洗涤1次，DCM洗涤一次，甲醇洗涤一次，DCM洗涤一次，DMF洗涤2次（这里使用甲醇和DCM交替洗涤，是为了更好地去除其他溶质，有利于后续反应）。得到 Fmoc-Cys(Trt)-CTC Resin。结构图如下：
2、脱Fmoc：加3倍树脂体积的20%Pip/DMF溶液，鼓氮气30分钟，然后2倍树脂体积的DMF 洗涤5次。得到 H2N-Cys(Trt)-CTC Resin 。（此步骤脱除Fmoc基团，茚三酮检测为蓝色，Pip为哌啶）。结构图如下：
3、缩合：取2.38mmol Fmoc-Val-OH 氨基酸，加入到上述树脂里，加适当DMF溶解氨基酸，再依次加入4.76mmol DIPEA，2.26mmol HBTU。反应30分钟后，取小样洗涤，茚三酮检测为无色。用2倍树脂体积的DMF 洗涤3次树脂。（洗涤树脂，去掉残留溶剂，为下一步反应做准备）。得到Fmoc-Val-Cys(Trt)-CTC Resin。氨基酸：DIPEA：HBTU：树脂=3：6：2.85：1（摩尔比）。结构图如下：
4、依次循环步骤二、步骤三，依次得到
H2N-Val-Cys(Trt)-CTC Resin
Fmoc-Asn(Trt)-Val-Cys(Trt)-CTC Resin
H2N-Asn(Trt)-Val-Cys(Trt)-CTC Resin
Fmoc-Gln(Trt)-Asn(Trt)-Val-Cys(Trt)-CTC Resin
H2N-Gln(Trt)-Asn(Trt)-Val-Cys(Trt)-CTC Resin
Fmoc-Arg(Pbf)-Gln(Trt)-Asn(Trt)-Val-Cys(Trt)-CTC Resin
H2N-Arg(Pbf)-Gln(Trt)-Asn(Trt)-Val-Cys(Trt)-CTC Resin
Fmoc-Gln(Trt)-Arg(Pbf)-Gln(Trt)-Asn(Trt)-Val-Cys(Trt)-CTC Resin
H2N-Gln(Trt)-Arg(Pbf)-Gln(Trt)-Asn(Trt)-Val-Cys(Trt)-CTC Resin
Fmoc-Asn(Trt)-Gln(Trt)-Arg(Pbf)-Gln(Trt)-Asn(Trt)-Val-Cys(Trt)-CTC Resin
H2N-Asn(Trt)-Gln(Trt)-Arg(Pbf)-Gln(Trt)-Asn(Trt)-Val-Cys(Trt)-CTC Resin
Fmoc-Pro-Asn(Trt)-Gln(Trt)-Arg(Pbf)-Gln(Trt)-Asn(Trt)-Val-Cys(Trt)-CTC Resin
H2N-Pro-Asn(Trt)-Gln(Trt)-Arg(Pbf)-Gln(Trt)-Asn(Trt)-Val-Cys(Trt)-CTC Resin
Fmoc-Thr(tBu)-Pro-Asn(Trt)-Gln(Trt)-Arg(Pbf)-Gln(Trt)-Asn(Trt)-Val-Cys(Trt)-CTC Resin
以上中间结构，均可在专肽生物多肽计算器-多肽结构计算器中，一键画出。
最后再经过步骤二得到 H2N-Thr(tBu)-Pro-Asn(Trt)-Gln(Trt)-Arg(Pbf)-Gln(Trt)-Asn(Trt)-Val-Cys(Trt)-CTC Resin，结构如下：
5、切割：6倍树脂体积的切割液（或每1g树脂加8ml左右的切割液），摇床摇晃 2小时，过滤掉树脂，用冰无水乙醚沉淀滤液，并用冰无水乙醚洗涤沉淀物3次，最后将沉淀物放真空干燥釜中，常温干燥24小试，得到粗品H2N-Thr-Pro-Asn-Gln-Arg-Gln-Asn-Val-Cys-COOH。结构图见产品结构图。
切割液选择：1）TFA：H2O=95%：5%、TFA：H2O=97.5%：2.5%
2）TFA：H2O：TIS=95%：2.5%：2.5%
3）三氟乙酸：茴香硫醚：1，2-乙二硫醇：苯酚：水=87.5%：5%：2.5%：2.5%：2.5%
（前两种适合没有容易氧化的氨基酸，例如Trp、Cys、Met。第三种适合几乎所有的序列。）
6、纯化冻干：使用液相色谱纯化，收集目标峰液体，进行冻干，获得蓬松的粉末状固体多肽。不过这时要取小样复测下纯度 是否目标纯度。
7、最后总结：
杭州专肽生物技术有限公司（ALLPEPTIDE https://www.allpeptide.com）主营定制多肽合成业务，提供各类长肽，短肽，环肽，提供各类修饰肽，如：荧光标记修饰（CY3、CY5、CY5.5、CY7、FAM、FITC、Rhodamine B、TAMRA等），功能基团修饰肽（叠氮、炔基、DBCO、DOTA、NOTA等），同位素标记肽（N15、C13），订书肽（Stapled Peptide）,脂肪酸修饰肽（Pal、Myr、Ste），磷酸化修饰肽（P-Ser、P-Thr、P-Tyr），环肽（酰胺键环肽、一对或者多对二硫键环），生物素标记肽，PEG修饰肽，甲基化修饰肽
以上所有内容，为专肽生物原创内容，请勿发布到其他网站上。
